HealthEquity (HQY)
(Delayed Data from NSDQ)
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$98.82 USD
+1.62 (1.67%)
Updated Nov 8, 2024 03:59 PM ET
After-Market: $98.64 -0.18 (-0.18%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth D Momentum B VGM
Zacks News
Why HealthEquity (HQY) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
IceCure Medical Ltd. (ICCM) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IceCure Medical Ltd. (ICCM) delivered earnings and revenue surprises of 11.11% and 25.26%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Doximity (DOCS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 17.65% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
TRxADE (MEDS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
TRxADE (MEDS) delivered earnings and revenue surprises of -50% and 8.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 50% and 0.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sera Prognostics, Inc. (SERA) Reports Q1 Loss
by Zacks Equity Research
Sera Prognostics, Inc. (SERA) delivered earnings and revenue surprises of 2.86% and 0%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will HealthEquity (HQY) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
HealthEquity (HQY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
HealthEquity (HQY) New Tie Up to Meet Clients' Healthcare Needs
by Zacks Equity Research
HealthEquity's (HQY) latest collaboration is expected to enhance digital transformation with Microsoft Azure and build better experiences for customers and employees.
HealthEquity (HQY) Beats on Q4 Earnings, Margins Rise
by Zacks Equity Research
HealthEquity (HQY) witnesses solid growth in HSAs, alongside recording robust performances in all its segments, in the fourth quarter of fiscal 2023.
HealthEquity (HQY) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered earnings and revenue surprises of 8.82% and 1.92%, respectively, for the quarter ended January 2023. Do the numbers hold clues to what lies ahead for the stock?
HealthEquity (HQY) Surges 10.0%: Is This an Indication of Further Gains?
by Zacks Equity Research
HealthEquity (HQY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
HealthEquity (HQY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
HealthEquity (HQY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cano Health, Inc. (CANO) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cano Health, Inc. (CANO) delivered earnings and revenue surprises of 280% and 3.83%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Retain HealthEquity (HQY) Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
Humana (HUM) Subsidiary Wins $70.8B DoD East Region Contract
by Zacks Equity Research
The latest award marks Humana's (HUM) military subsidiary's sixth TRICARE contract win.
Here's Why You Should Retain Inari Medical (NARI) Stock Now
by Zacks Equity Research
Inari Medical (NARI) continues to benefit from its commitment to understanding the venous system. However, dependency on the wide adoption of products is a woe.
Reasons to Retain AmerisourceBergen (ABC) in Your Portfolio
by Zacks Equity Research
AmerisourceBergen (ABC) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.
Here's Why You Should Bet on ShockWave Medical (SWAV) Stock
by Zacks Equity Research
ShockWave Medical (SWAV) continues to benefit from solid R&D endeavors and its commitment to clinical studies.
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.
Here's What You Should Know From Centene's (CNC) 2023 Outlook
by Zacks Equity Research
Centene's (CNC) board boosts its share buyback program with a new $2-billion fund.
Here's Why You Should Retain Patterson Companies (PDCO) Stock
by Zacks Equity Research
Investors are optimistic about Patterson Companies (PDCO) on the back of its strong product line.
Stryker's (SYK) Citrefix to Boost Foot and Ankle Surgeries
by Zacks Equity Research
Stryker's (SYK) newly-launched Citrefix will help customers avoid chronic inflammation using Citregen. Its pull-out strength is greatly increased compared to other suture anchors.
Zacks Industry Outlook Highlights Medpace, HealthEquity and Progyny
by Zacks Equity Research
Medpace, HealthEquity and Progyny have been highlighted in this Industry Outlook article.
3 Medical Services Stocks to Buy Amid Industry Challenges
by Urmimala Biswas
The Zacks Medical - Services industry is growing on digital healthcare adoption. MEDP, HQY and PGNY are set to gain the most. However, staffing shortages may disrupt the trend.